Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Agminated segmental nevi demonstrating intranevic concordance of BRAF status.

Luo S, Chaplin AC, Langley RG, Njauw CN, Duncan LM, Miller RA, Tsao H.

J Invest Dermatol. 2011 Mar;131(3):788-90. doi: 10.1038/jid.2010.380. Epub 2010 Dec 16. No abstract available.

2.

The dermoscopical and histopathological patterns of nevi correlate with the frequency of BRAF mutations.

Zalaudek I, Guelly C, Pellacani G, Hofmann-Wellenhof R, Trajanoski S, Kittler H, Scope A, Marghoob AA, Longo C, Leinweber B, Ferrara G, Saida T, Grichnik JM, Argenziano G, Becker JC.

J Invest Dermatol. 2011 Feb;131(2):542-5. doi: 10.1038/jid.2010.332. Epub 2010 Nov 11. No abstract available.

3.

Benign nodal nevi frequently harbor the activating V600E BRAF mutation.

Taube JM, Begum S, Shi C, Eshleman JR, Westra WH.

Am J Surg Pathol. 2009 Apr;33(4):568-71. doi: 10.1097/PAS.0b013e31818a64fb.

PMID:
19033861
4.

High frequency of BRAFV600E mutation in acquired nevi and small congenital nevi, but low frequency of mutation in medium-sized congenital nevi.

Ichii-Nakato N, Takata M, Takayanagi S, Takashima S, Lin J, Murata H, Fujimoto A, Hatta N, Saida T.

J Invest Dermatol. 2006 Sep;126(9):2111-8. Epub 2006 May 11.

5.

BRAFV600E mutation status of involuting and stable nevi in dabrafenib therapy with or without trametinib.

McClenahan P, Lin LL, Tan JM, Flewell-Smith R, Schaider H, Jagirdar K, Atkinson V, Lambie D, Prow TW, Sturm RA, Soyer HP.

JAMA Dermatol. 2014 Oct;150(10):1079-82. doi: 10.1001/jamadermatol.2014.436.

PMID:
24695877
6.

Distribution of BRAF T1799A(V600E) mutations across various types of benign nevi: implications for melanocytic tumorigenesis.

Wu J, Rosenbaum E, Begum S, Westra WH.

Am J Dermatopathol. 2007 Dec;29(6):534-7.

PMID:
18032947
7.

Detection of the BRAF V600E mutation in melanocytic lesions using the ligase detection reaction.

Turner DJ, Zirvi MA, Barany F, Elenitsas R, Seykora J.

J Cutan Pathol. 2005 May;32(5):334-9.

PMID:
15811117
8.

Predictors of BRAF mutation in melanocytic nevi: analysis across regions with different UV radiation exposure.

Karram S, Novy M, Saroufim M, Loya A, Taraif S, Houreih MA, Rauscher B, Habib RH, Oberkanins C, Khalifeh I.

Am J Dermatopathol. 2013 Jun;35(4):412-8. doi: 10.1097/DAD.0b013e31826db181.

PMID:
23051629
9.

Melanocytic nevi excised during B-Raf proto-oncogene (BRAF) inhibitor therapy: A study of 19 lesions from 10 patients.

Mochel MC, Hammond MR, Frederick DT, Alora-Palli MB, Piris A, Flaherty KT, Hoang MP.

J Am Acad Dermatol. 2015 Sep;73(3):491-9.e2. doi: 10.1016/j.jaad.2015.06.006. Epub 2015 Jul 16.

PMID:
26190239
10.

NRAS and BRAF mutations in melanoma-associated nevi and uninvolved nevi.

Tschandl P, Berghoff AS, Preusser M, Burgstaller-Muehlbacher S, Pehamberger H, Okamoto I, Kittler H.

PLoS One. 2013 Jul 8;8(7):e69639. doi: 10.1371/journal.pone.0069639. Print 2013.

11.

What dermoscopy tells us about nevogenesis.

Zalaudek I, Catricalà C, Moscarella E, Argenziano G.

J Dermatol. 2011 Jan;38(1):16-24. doi: 10.1111/j.1346-8138.2010.01141.x.

PMID:
21175751
12.

BRAF analysis on a spectrum of melanocytic neoplasms: an epidemiological study across differing UV regions.

Saroufim M, Habib R, Karram S, Youssef Massad C, Taraif S, Loya A, Houreih MA, Sheikh SS, Amr SS, Satti M, Oberkanins C, Khalifeh I.

Am J Dermatopathol. 2014 Jan;36(1):68-73. doi: 10.1097/DAD.0b013e318293f355.

PMID:
23782679
13.

BRAF mutations in melanocytic tumors (nevi and melanomas) from organ transplant recipients.

Kanitakis J, Baldassini S, Lora V, Euvrard S.

Eur J Dermatol. 2010 Mar-Apr;20(2):167-71. doi: 10.1684/ejd.2010.0843. Epub 2009 Nov 17.

PMID:
19919912
14.

Lack of association between BRAF mutation and MAPK ERK activation in melanocytic nevi.

Uribe P, Andrade L, Gonzalez S.

J Invest Dermatol. 2006 Jan;126(1):161-6.

15.

Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice.

Goel VK, Ibrahim N, Jiang G, Singhal M, Fee S, Flotte T, Westmoreland S, Haluska FS, Hinds PW, Haluska FG.

Oncogene. 2009 Jun 11;28(23):2289-98. doi: 10.1038/onc.2009.95. Epub 2009 Apr 27.

16.

Mutations of the BRAF gene in benign and malignant melanocytic lesions.

Yazdi AS, Palmedo G, Flaig MJ, Puchta U, Reckwerth A, Rütten A, Mentzel T, Hügel H, Hantschke M, Schmid-Wendtner MH, Kutzner H, Sander CA.

J Invest Dermatol. 2003 Nov;121(5):1160-2.

17.

BRAF and NRAS mutations in spitzoid melanocytic lesions.

Fullen DR, Poynter JN, Lowe L, Su LD, Elder JT, Nair RP, Johnson TM, Gruber SB.

Mod Pathol. 2006 Oct;19(10):1324-32. Epub 2006 Jun 23.

18.

Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma.

Thomas NE, Edmiston SN, Alexander A, Millikan RC, Groben PA, Hao H, Tolbert D, Berwick M, Busam K, Begg CB, Mattingly D, Ollila DW, Tse CK, Hummer A, Lee-Taylor J, Conway K.

Cancer Epidemiol Biomarkers Prev. 2007 May;16(5):991-7.

19.

Activating mutations in the RAS/mitogen-activated protein kinase signaling pathway in sporadic trichoblastoma and syringocystadenoma papilliferum.

Shen AS, Peterhof E, Kind P, Rütten A, Zelger B, Landthaler M, Berneburg M, Hafner C, Groesser L.

Hum Pathol. 2015 Feb;46(2):272-6. doi: 10.1016/j.humpath.2014.11.002. Epub 2014 Nov 15.

PMID:
25532942
20.

Exon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites.

Cohen Y, Rosenbaum E, Begum S, Goldenberg D, Esche C, Lavie O, Sidransky D, Westra WH.

Clin Cancer Res. 2004 May 15;10(10):3444-7.

Supplemental Content

Support Center